Cargando…

Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance

The aim of this study was to obtain real-world, US, observational data on the effect of baseline resistance-associated substitutions (RASs) on achieving sustained virologic response (SVR) in hepatitis C (HCV) patients treated with direct-acting antiviral (DAA) regimens; the need for long-term follow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loo, Nicole, Hanysak, Bryan, Mann, Jena, Ramirez, Ruben, Kim, Jae, Mitchell, Robert, Van Frank, Timothy, Guerrero, Richard, Hinojosa, Kim, Christensen, Kimberley, Pedicone, Lisa D., Alkhouri, Naim, Wells, Jennifer, Landaverde, Carmen, Rodas, Fabian, Lawitz, Eric, Poordad, Fred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617322/ https://www.ncbi.nlm.nih.gov/pubmed/31261592 http://dx.doi.org/10.1097/MD.0000000000016254

Ejemplares similares

Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients
por: Loo, Nicole, et al.
Publicado: (2019)

High sustained virologic response rates, regardless of race or socioeconomic class, in patients treated with chronic hepatitis C in community practice using a specialized pharmacy team
por: Kuwelker, Saatchi, et al.
Publicado: (2023)

Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes
por: Alkhouri, Naim, et al.
Publicado: (2018)

Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort
por: Khoudari, George, et al.
Publicado: (2019)

Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment
por: Alkhouri, Naim, et al.
Publicado: (2019)

An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin
por: Poordad, Fred, et al.
Publicado: (2017)

Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies
por: Poordad, Fred, et al.
Publicado: (2020)

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
por: Feld, Jordan J., et al.
Publicado: (2016)

Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response
por: Pal, Vabhave, et al.
Publicado: (2020)

Molecular Epidemiology and Baseline Resistance of Hepatitis C Virus to Direct Acting Antivirals in Croatia
por: Simicic, Petra, et al.
Publicado: (2022)

Cholestasis in Benign Recurrent Intrahepatic Cholestasis 2
por: Arthur Lorio, Eric, et al.
Publicado: (2020)

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
por: Poordad, Fred, et al.
Publicado: (2017)

Big Changes Are Coming in Hepatitis C
por: Poordad, Fred
Publicado: (2010)

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
por: Lawitz, Eric J., et al.
Publicado: (2016)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
por: Poordad, Fred, et al.
Publicado: (2018)

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
por: Lawitz, Eric, et al.
Publicado: (2015)

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study
por: Lawitz, Eric, et al.
Publicado: (2020)

Viral Resistance in Hepatitis B: Prevalence and Management
por: Poordad, Fred, et al.
Publicado: (2010)

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
por: Lawitz, Eric J., et al.
Publicado: (2021)

Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment
por: Kai, Yugo, et al.
Publicado: (2017)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

High antiviral activity of NS5A inhibitor ABT‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection
por: Poordad, Fred, et al.
Publicado: (2016)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
por: Abu-Freha, Naim, et al.
Publicado: (2023)

Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy
por: Chen, Yen-Chun, et al.
Publicado: (2021)

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2021)

Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus
por: Tahata, Yuki, et al.
Publicado: (2023)

Hereditary Hemorrhagic Telangiectasia With Liver Vascular Malformation Presenting With High-Output Heart Failure
por: Singh, Gurshawn, et al.
Publicado: (2014)

Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?
por: Tomah, Shaheen, et al.
Publicado: (2020)

Long-acting antiviral agents for HIV treatment
por: Margolis, David A., et al.
Publicado: (2015)

Influenza Antiviral Subversion: Now the Host Is in on the Act
por: Yepsen, Erin N., et al.
Publicado: (2021)

What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
por: Kim, Jin-Wook
Publicado: (2019)

Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints
por: Alkhouri, Naim, et al.
Publicado: (2019)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Calcium-sensing receptor acts as an antiviral factor for rotavirus infections and participates in cellular antiviral response
por: Huang, Haohai, et al.
Publicado: (2022)

Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW
por: Tripathy, Devjit, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bpudbsgctb1v215p04vt2j58al